Clinical trials in Poitiers – page 31

619 clinical trials in Poitiers, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Poitiers at a glance

619

clinical trials

Research sites1

Quick filters

619 trials in Poitiers

Open in trial search

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:Celcuity Inc.

Contact Research Centre

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational

France

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational

France

Participants:18–64 years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Pericarditis

Not recruiting

Study of Cannabidiol for Treatment of Recurrent Pericarditis in Affected Patients

InvestigationalNo placebo

Study of Cannabidiol for Treatment of Recurrent Pericarditis in Affected Patients

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cannabidiol
Sponsor:Cardiol Therapeutics Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo

Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Cabozantinib
Sponsor:Ipsen Innovation

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Pulmonary arterial hypertension

Not recruiting

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sotatercept
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational

France

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo

Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Gastric cancer

Not recruiting

Study of FOLFIRI with Domvanalimab and Zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

Registered drugNo placebo

Study of FOLFIRI with Domvanalimab and Zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Domvanalimab
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Poitiers

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and various advanced cancers. Studies are evaluating novel therapeutic combinations and treatment strategies for better patient outcomes.

Advanced Gastric Cancer Treatments
Pancreatic Adenocarcinoma Therapy
Myelodysplastic Syndromes

Several trials are investigating targeted therapies and immunotherapy approaches for various cancer types.

02 Neurological Studies

Research focusing on essential tremor treatments and innovative therapeutic approaches. Clinical trials are evaluating new medications for movement disorders.

Movement Disorders
Neurological Conditions
Early Psychosis Treatment

Studies aim to improve patient quality of life through novel therapeutic interventions.

03 Transplant Medicine

Advanced research in kidney transplantation and post-transplant care, including studies on antibody-mediated rejection prevention and treatment strategies.

Organ Transplantation
Immunosuppression Protocols
Rejection Prevention

Trials focus on improving long-term outcomes for transplant recipients.

04 Critical Care Medicine

Studies evaluating postoperative care and pain management in critical care settings, including innovative approaches to patient comfort and recovery.

Pain Management
Postoperative Care
Patient Comfort Optimization

Research aims to enhance patient comfort and recovery in intensive care settings.

Back to France All countries